n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)

Latest News

Our new retail holding Fifth & Pacific is a high performer

Our new retail holding Fifth & Pacific is a high performer

Fifth & Pacific's stock is rising on speculation it will sell off Lucky Brand business.

Investors Expect too Much of Salix

Investors Expect too Much of Salix

There are still too many unknowns about the pipeline to suggest there is further value here.

Short Interest In Santarus Plummets 69.6%

Short Interest In Santarus Plummets 69.6%

The most recent short interest data has been released by the NASDAQ for the 11/15/2013 settlement date, which shows a 3,914,806 share decrease in total short interest for Santarus Inc , to 1,711,509, a decrease of 69.58% since 10/31/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Santarus, Inc. Stockholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Santarus, Inc. Stockholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Santarus, Inc.

Wolf Haldenstein Announces Investigation Of Acquisition Of Santarus, Inc.

Wolf Haldenstein Announces Investigation Of Acquisition Of Santarus, Inc.

Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) is investigating the acquisition of Santarus, Inc.

Santarus Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Salix Pharma

Santarus Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Acquisition By Salix Pharma

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Santarus,...

Investor Alert: Holzer Holzer & Fistel, LLC Announces Investigation Into The Proposed Buyout Of Santarus, Inc.

Investor Alert: Holzer Holzer & Fistel, LLC Announces Investigation Into The Proposed Buyout Of Santarus, Inc.

Holzer Holzer & Fistel, LLC is investigating whether the directors of Santarus, Inc.

SANTARUS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Santarus, Inc. (SNTS) Over The Proposed Sale Of The Company To Salix Pharmaceuticals Ltd. (SLXP)

SANTARUS SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Santarus, Inc. (SNTS) Over The Proposed Sale Of The Company To Salix Pharmaceuticals Ltd. (SLXP)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Santarus, Inc.

Finkelstein Thompson LLP Announces Investigation Of Santarus, Inc. Buyout Proposal

Finkelstein Thompson LLP Announces Investigation Of Santarus, Inc. Buyout Proposal

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Santarus, Inc.

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Buyer views target's diabetes and heartburn treatments as complementary to its drug lineup.

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of The Santarus, Inc. Proposed Acquisition By Salix Pharmaceuticals, Ltd.

Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of The Santarus, Inc. Proposed Acquisition By Salix Pharmaceuticals, Ltd.

Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating whether the Board of Directors of Santarus, Inc.

Law Firm Brower Piven Announces Investigation Of Santarus, Inc. Proposed Buyout

Law Firm Brower Piven Announces Investigation Of Santarus, Inc. Proposed Buyout

The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Santarus, Inc.

Santarus (SNTS): Heavy Pre-Market Activity

Santarus (SNTS): Heavy Pre-Market Activity

Trade-Ideas LLC identified Santarus (SNTS) as a pre-market mover with heavy volume candidate

LEVI & KORSINSKY, LLP Notifies Investors Of SANTARUS, INC. Of Claims Of Breaches Of Fiduciary Duty By Board Of The Company In Connection With Sale Of The Company To Salix Pharmaceuticals, Ltd.

LEVI & KORSINSKY, LLP Notifies Investors Of SANTARUS, INC. Of Claims Of Breaches Of Fiduciary Duty By Board Of The Company In Connection With Sale Of The Company To Salix Pharmaceuticals, Ltd.

Levi & Korsinsky notifies investors of Santarus, Inc. (“Santarus” or the “Company”) (Nasdaq:SNTS) for possible breaches of fiduciary duty and other violations of state law in connection with the...

Santarus And Pharming Announce New Data From Open-Label Repeat Treatment Study With RUCONEST (Recombinant Human C1 Esterase Inhibitor)

Santarus And Pharming Announce New Data From Open-Label Repeat Treatment Study With RUCONEST (Recombinant Human C1 Esterase Inhibitor)

Santarus, Inc. (NASDAQ:SNTS) and Pharming Group NV (NYSE Euronext: PHARM) announced that new data from an open-label extension of the pivotal Phase III clinical study with RUCONEST ® (recombinant human C1 esterase...

The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of Santarus, Inc. By Salix Pharmaceuticals, Ltd.

The Law Firm Of Wohl & Fruchter Is Investigating The Acquisition Of Santarus, Inc. By Salix Pharmaceuticals, Ltd.

The law firm of Wohl & Fruchter LLP is investigating the proposed acquisition of Santarus, Inc.

Salix Pharma to Acquire Santarus

Salix Pharma to Acquire Santarus

Salix Pharmaceuticals announced it will acquire Santarus in a deal worth $2.6 billion.

LEVI & KORSINSKY, LLP Notifies Investors Of SANTARUS, INC. Of Claims Of Breaches Of Fiduciary Duty By Board Of The Company In Connection With Sale Of The Company To Salix Pharmaceuticals, Ltd.

LEVI & KORSINSKY, LLP Notifies Investors Of SANTARUS, INC. Of Claims Of Breaches Of Fiduciary Duty By Board Of The Company In Connection With Sale Of The Company To Salix Pharmaceuticals, Ltd.

Levi & Korsinsky notifies investors of Santarus, Inc. (“Santarus” or the “Company”) (Nasdaq:SNTS) for possible breaches of fiduciary duty and other violations of state law in connection with the...

Santarus Reports Third Quarter 2013 Financial Results

Santarus Reports Third Quarter 2013 Financial Results

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the quarter and nine months ended September 30, 2013.

Salix Pharmaceuticals To Acquire Santarus

Salix Pharmaceuticals To Acquire Santarus

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Santarus, Inc.

Santarus To Hold Third Quarter 2013 Financial Results Conference Call On November 7

Santarus To Hold Third Quarter 2013 Financial Results Conference Call On November 7

Santarus, Inc. (NASDAQ:SNTS) today announced that it will release third quarter 2013 financial results after market close on Thursday, November 7, 2013.

Santarus Announces Presentation Of SAN-300 Phase I Data At 2013 American College Of Rheumatology Annual Meeting

Santarus Announces Presentation Of SAN-300 Phase I Data At 2013 American College Of Rheumatology Annual Meeting

Santarus, Inc. (NASDAQ:SNTS) today announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; α1β1 integrin), will...

Interesting SNTS Put And Call Options For December 21st

Interesting SNTS Put And Call Options For December 21st

Investors in Santarus Inc saw new options become available this week, for the December 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SNTS options chain for the new December 21st contracts and identified one put and one call contract of particular interest.

Insider Trading Alert - Santarus And 4 Others Traded By Insiders

Insider Trading Alert - Santarus And 4 Others Traded By Insiders

Stocks with insider trader activity include SNTS, DWRE, RHP, MKL and LNKD

Top Insider Trades: USCR ACCL SNTS RHP

Top Insider Trades: USCR ACCL SNTS RHP

The top 10 open-market insider purchases and sales filed at the SEC Wednesday.

Santarus Announces Presentation Of Phase III Data For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus Announces Presentation Of Phase III Data For Rifamycin SV MMX In Travelers’ Diarrhea

Santarus, Inc. (NASDAQ:SNTS) today announced that new data from its Phase III clinical study with the investigational drug rifamycin SV MMX ® in patients with travelers’ diarrhea will be featured in a...